SPP1 and rheumatoid arthritis: Preclinical efforts to target OPN have shown promise, with evidence suggesting that OPN inhibition attenuates inflammatory responses and reduces joint destruction, reinforcing its potential as a biomarker and therapeutic target in RA [16].